Clinical trial
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients…
NCT00486213 · National Cancer Centre, Singapore, Other · Terminated
Key facts
| NCT number | NCT00486213 |
|---|---|
| Title | Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer |
| Official title | Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS) |
| Lead sponsor | National Cancer Centre, Singapore, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Dietary Supplement, Other |
| Interventions | pyridoxine hydrochloride, Placebo |
| Enrollment | 210 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | Jun 14, 2007 |
| Last update posted | Sep 24, 2015 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: